Link: https://links.sgx.com/1.0.0/corporate-announcements/96UY881MRVY9SA4O/75ab68b74676fe26d469a8b77c13d1849eea3cfff4b603ee32bd2a62d127395e

Summary:

• Group revenue declined 19.2% to S$6.1 million (FY2024: S$7.54 million), mainly due to lower U.S. sales impacted by tariffs and market uncertainties.

• Net loss widened to S$2.87 million (FY2025) from S$2.08 million (FY2024), driven by higher staff costs (including share-based expenses), full-year consolidation of Digital Life Line Pte. Ltd. (DLL), and ongoing legal/professional fees.

• No dividend declared for FY2025, as management remains conservative amidst continued losses.

• Group cash and cash equivalents nearly doubled to S$2.71 million, mainly from Rights Cum Warrants Issue proceeds of S$3.15 million in June 2025.

• Net assets increased to S$2.35 million due to the capital raising, despite operational losses.

• Notable business activities:

  • Commercial focus on U.S. major retailer with RFID serialization technology to address return fraud; significant commercialization opportunity pending contract finalization.

  • Considered discontinuing less profitable semiconductor trading to focus on core tech solutions and healthcare.

  • DLL’s vision screening technology and healthcare solutions in Singapore and Hong Kong progressing; new clinical trials and product development on track for 2026.

  • Acquired 50% of Rheumatology Associates Pte. Ltd. for healthcare sector expansion.

• Group’s strategic outlook emphasizes scaling core technology, healthcare innovation, and prudent capital allocation for sustainable growth.